Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 3/2021

01-06-2021 | Ticagrelor | Review Article

Effect of Desmopressin on Platelet Dysfunction During Antiplatelet Therapy: A Systematic Review

Authors: Lise Kjær Andersen, Anne-Mette Hvas, Christine Lodberg Hvas

Published in: Neurocritical Care | Issue 3/2021

Login to get access

Abstract

Background and Objective

An increasing number of patients receive antiplatelet therapy. Patients exposed to surgery while receiving platelet inhibitors hold an increased bleeding risk. Especially in neurosurgery and neurocritical care patients, bleeding and hematoma expansion are feared complications as even minor bleedings may be hazardous. The objective of this systematic review was to investigate the effect of desmopressin (1-deamino-8-d-arginine vasopressin, DDAVP) on platelet function during antiplatelet therapy in patients undergoing non-cardiac surgery, patients who experience spontaneous or traumatic hemorrhage, healthy individuals and in animals.

Methods

Studies were identified through a systematic literature search in PubMed and EMBASE on August 19, 2019, with an update on May 2, 2020, and from reference lists of the included studies. Data on clinical and biochemical effect of DDAVP were extracted from included studies for a qualitative data synthesis.

Results

In total, 22 studies were included: 18 human studies and four animal studies. Overall, DDAVP improved bleeding time and increased platelet aggregation in patients undergoing non-cardiac surgery, patients suffering intracerebral or subarachnoid hemorrhage while receiving antiplatelet therapy as well as in healthy individuals and animals exposed to antiplatelet therapy. Observational data indicate that DDAVP may mitigate hematoma expansion in patients with intracerebral hemorrhage or traumatic brain injury.

Conclusions

The present data hold biochemical evidence that DDAVP improves platelet function during antiplatelet therapy in humans and animals. The need for randomized trials is evident in order to evaluate the potential clinical effect of DDAVP in management of patients with spontaneous or traumatic hemorrhage, or undergoing neurosurgery, while receiving antiplatelet therapy.
Literature
1.
Spahn, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98.PubMedPubMedCentral
2.
Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis. 2004;17(1):21–7.PubMed
3.
van den Brand CL, Tolido T, Rambach AH, Hunink MG, Patka P, Jellema K. Systematic review and meta-analysis: Is pre-injury antiplatelet therapy associated with traumatic intracranial hemorrhage? J Neurotrauma. 2017;34(1):1–7.PubMed
4.
Thorn S, Guting H, Mathes T, Schafer N, Maegele M. The effect of platelet transfusion in patients with traumatic brain injury and concomitant antiplatelet use: a systematic review and meta-analysis. Transfusion. 2019;59(11):3536–44.PubMed
5.
Williams CD, Chan AT, Elman MR, Kristensen AH, Miser WF, Pignone MP, et al. Aspirin use among adults in the U.S.: results of a national survey. Am J Prev Med. 2015;48(5):501–8.PubMed
6.
Song JW, Soh S, Shim JK. Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. Korean J Anesthesiol. 2017;70(1):13–21.PubMedPubMedCentral
7.
Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. Br J Anaesth. 2013;111(Suppl 1):i3–17.PubMed
8.
Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol. 2017;34(6):332–95.PubMed
9.
Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20(1):100.PubMedPubMedCentral
10.
Frontera JA, Lewin IJJ, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocritical Care. 2016;24(1):6–46.PubMed
11.
Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759–69.PubMed
12.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515–21.PubMed
13.
Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol. 1992;49(1):7–13.PubMed
14.
Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30(6):270–382.PubMed
15.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.PubMed
16.
Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom haemophilia centre doctors organization guideline approved by the british committee for standards in haematology. Br J Haematol. 2014;167(4):453–65.PubMedPubMedCentral
17.
Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83(977):159–63.PubMedPubMedCentral
18.
Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia. 2008;14(Suppl 1):31–9.PubMed
19.
Desborough MJ, Oakland KA, Landoni G, Crivellari M, Doree C, Estcourt LJ, et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2017;15(2):263–72.PubMed
20.
Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol. 2007;82(8):731–5.PubMed
21.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentral
22.
23.
Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg. 1993;80(6):723–4.PubMed
24.
Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol. 2015;94(9):1457–61.PubMed
25.
Francoeur CL, Roh D, Michael Schmidt J, Mayer SA, Cristina Falo M, Agarwal S, et al. Desmopressin administration and rebleeding in subarachnoid hemorrhage: analysis of an observational prospective database. J Neurosurg. 2019;130(2):502–8.
26.
Schmidt KJ, Sager B, Zachariah J, Raad BF, James EG, Fletcher JJ. Cohort analysis of desmopressin effect on hematoma expansion in patients with spontaneous intracerebral hemorrhage and documented pre-ictus antiplatelet use. J Clin Neurosci. 2019;66:33–7.PubMed
27.
Feldman EA, Meola G, Zyck S, Miller CD, Krishnamurthy S, Cwikla GM, et al. Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage. Crit Care Med. 2019;47(12):1759–65.PubMed
28.
Mengel A, Stefanou MI, Hadaschik KA, Wolf M, Stadler V, Poli K, et al. Early administration of desmopressin and platelet transfusion for reducing hematoma expansion in patients with acute antiplatelet therapy associated intracerebral hemorrhage. Crit Care Med. 2020;48:1009–17.PubMed
29.
Barletta JF, Abdul-Rahman D, Hall ST, Mangram AJ, Dzandu JK, Frontera JA, et al. The role of desmopressin on hematoma expansion in patients with mild traumatic brain injury prescribed pre-injury antiplatelet medications. Neurocrit Care 2020.
30.
Kapapa T, Rohrer S, Struve S, Petscher M, Konig R, Wirtz CR, et al. Desmopressin acetate in intracranial haemorrhage. Neurol Res Int. 2014;2014:298767.PubMedPubMedCentral
31.
Van Genderen PJJ, Van Vliet HHDM, Prins FJ, Van De Moesdijk D, Van Strik R, Zijlstra FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol. 1997;75(5–6):215–20.PubMed
32.
Lethagen S, Olofsson L, Frick K, Berntorp E, Bjorkman S. Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo. Haemophilia. 2000;6(1):15–20.PubMed
33.
Lethagen S, Rugarn P. The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetyl salicylic acid intake in healthy volunteers. Thromb Haemost. 1992;67(1):185–6.PubMed
34.
Reiter R, Jilma-Stohlawetz P, Horvath M, Jilma B. Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion. 2005;45(3):420–6.PubMed
35.
Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003;102(13):4594–9.PubMed
36.
Schulz-Stübner S, Zielske D, Rossaint R. Comparison between nasal and intravenous desmopressin for the treatment of aminosalicylic acid-induced platelet dysfunction. Eur J Anaesthesiol. 2002;19(9):647–51.PubMed
37.
Tsui PY, Cheung CW, Lee Y, Leung SW, Ng KF. The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin: a randomized controlled trial. BMC Anesthesiol. 2015;15:80.PubMedPubMedCentral
38.
Mannucci PM, Vicente V, Vianello L. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67(4):1148–53.PubMed
39.
Leithauser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1–4):293–302.PubMed
40.
Teng R, Mitchell PD, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Ther. 2014;39(2):186–91.PubMed
41.
Peter FW, Benkovic C, Muehlberger T, Vogt PM, Homann HH, Kuhnen C, et al. Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. Br J Haematol. 2002;117(3):658–63.PubMed
42.
Levine M, Swenson S, McCormick T, Henderson SO, Thomas SH, Markland FS. Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration. J Med Toxicol. 2013;9(2):139–43.PubMed
43.
Sakai M, Watari T, Miura T, Maruyama H, Koie H, Yamaya Y, et al. Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases. J Vet Med Sci. 2003;65(1):83–6.PubMed
44.
Bonhomme F, Lecompte T, Samama CM, Godier A, Fontana P. Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: a randomised, placebo-controlled study in a rabbit model. Eur J Anaesthesiol. 2018;35(3):208–14.PubMed
Metadata
Title
Effect of Desmopressin on Platelet Dysfunction During Antiplatelet Therapy: A Systematic Review
Authors
Lise Kjær Andersen
Anne-Mette Hvas
Christine Lodberg Hvas
Publication date
01-06-2021
Publisher
Springer US
Published in
Neurocritical Care / Issue 3/2021
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-020-01055-6

Other articles of this Issue 3/2021

Neurocritical Care 3/2021 Go to the issue

Neuro-Images

Looking Twice the Wrong Way: The Challenge of Diagnosing Acute Basilar Artery Occlusion

Original work

Intensive Care Unit—Acquired Weakness in Children: A Prospective Observational Study Using Simplified Serial Electrophysiological Testing (PEDCIMP Study)

Original Work

Temperature Variability Does Not Attenuate the Beneficial Effects of Therapeutic Hypothermia on Cellular Apoptosis and Endoplasmic Reticulum Stress in the Cerebral Cortex of a Swine Cardiac Arrest Model

Original Work

Association of Dexamethasone with Shunt Requirement, Early Disability, and Medical Complications in Aneurysmal Subarachnoid Hemorrhage

Original Work

Is Spreading Depolarization a Risk Factor for Late Epilepsy? A Prospective Study in Patients with Traumatic Brain Injury and Malignant Ischemic Stroke Undergoing Decompressive Craniectomy

Review Article

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review